NCT06037577View on ClinicalTrials.gov

Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 5, 2019

Primary Completion Date

May 5, 2019

Study Completion Date

May 5, 2019

Conditions

Nonalcoholic Steatohepatitis (NASH)Primary Sclerosing Cholangitis (PSC)Systemic Sclerosis (SSc)

Interventions

DRUG

CM-101

Anti-human CCL24 monoclonal antibody (CM-101)

DRUG

Placebo

Placebo Comparator

Trial Locations (1)

6423916

Tel Aviv Sourasky Medical Center, Tel Aviv

All Listed Sponsors

lead

ChemomAb Ltd.

INDUSTRY

NCT06037577 - Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects | Biotech Hunter | Biotech Hunter